

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Suzhou Ribo Life Science Co., Ltd.

蘇州瑞博生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6938)

VOLUNTARY ANNOUNCEMENT

PHASE I CLINICAL TRIAL APPLICATION SUBMISSION OF RBD3133 INJECTION FOR OVERWEIGHT AND OBESITY

This announcement is made by Suzhou Ribo Life Science Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide shareholders of the Company (the “**Shareholders**”) and potential investors with an update on the Group’s research and development progress.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce the submission of the Phase I clinical trial application for the Company’s INHBE-targeting siRNA product RBD3133 Injection for overweight and obesity as its therapeutic indication in EU.

Obesity has become one of the world’s most significant public health challenges, affecting more than one billion people globally and contributing to a substantial burden of type 2 diabetes, cardiovascular disease, and other obesity-related comorbidities. Despite recent advances in obesity treatment, there remains a significant need for innovative therapies that address the underlying biology of metabolic dysfunction and provide durable clinical benefit.

RBD3133 Injection is designed to selectively silence INHBE, a gene encoding the protein activin E. Human genetic studies have demonstrated that individuals carrying naturally occurring loss-of-function variants in INHBE exhibit healthier fat distribution, improved metabolic characteristics, and lower estimated risk of coronary heart disease and type 2 diabetes. These findings support INHBE as a promising therapeutic target for obesity and related metabolic diseases.

The Phase I study is a randomized, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered RBD3133 in participants with overweight or obesity. The trial will provide the first assessment of RBD3133 in humans and will establish the foundation for further clinical development.

The RBD3133 represents a pivotal step of the Company's siRNA development portfolio in the field of cardiovascular and metabolic disease and is poised to serve as a cornerstone drug for the treatment of weight-loss-related cardiovascular and metabolic disorders. As the Company's first candidate drug in the obesity therapeutic area, RBD3133 reflects the Company's strategic focus on developing innovative medicines for large patient populations with substantial unmet medical need.

RBD3133 Injection may not ultimately be successfully developed and commercialized. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Suzhou Ribo Life Science Co., Ltd.
LIANG Zicai
Chairman

Hong Kong, October 8, 2026

As of the date of this announcement, the executive Directors are Dr. LIANG Zicai, Dr. GAN Liming and Dr. ZHANG Hongyan, the non-executive Directors are Dr. QI Fei, Mr. LI Dongfang and Mr. LI Yuhui, and the independent non-executive Directors are Dr. YU Xuefeng, Mr. MA Chaosong and Mr. WANG Ruiping.